FDA Approval and Launch of Tyvaso® for the Treatment of Pulm

[wyattdog]

** Brokerage J.P.Morgan is optimistic about the market opportunity for United Therapeutics Corp's drug Tyvaso to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD) ** Raises PT to $212 from $185, implying an upside of about 11% to UTHR's last close ** The U.S. FDA earlier in the month approved use of the drug, which was already indicated for pulmonary arterial hypertension, to treat PH-ILD [nL4N2LU3C7] ** Brokerage says its survey showed most U.S. physicians found the drug's late-stage data promising and thought the product was safe and effective ** Within first year of approval, physicians anticipate putting >25% of PH-ILD patients on Tyvaso and expect this number to grow to >40% over the next five years - brokerage ** Brokerage Jefferies hosted a call with a pulmonary hypertension specialist, who expects Tyvaso use to at least double over the next year after expanded label; brokerage raises PT to $215 to $230 ** UTHR up 2.6% at $195.6; stock had risen about 26% YTD up to last close (Reporting by Amruta Khandekar) ((Amruta.Khandekar@thomsonreuters